Cargando…

High Mortality of HLH in ICU Regardless Etiology or Treatment

Background: Adult hemophagocytic lymphohistiocytosis (HLH) is highly lethal in the ICU. The diagnostic and therapeutic emergency that HLH represents is compounded by its unknown pathophysiological mechanisms. Here, we report on a large cohort of adult HLH in the ICU (ICU-HLH). We analyzed prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bichon, Amandine, Bourenne, Jérémy, Allardet-Servent, Jérôme, Papazian, Laurent, Hraiech, Sami, Guervilly, Christophe, Pauly, Vanessa, Kaplanski, Gilles, Mokart, Djamel, Gainnier, Marc, Carvelli, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526960/
https://www.ncbi.nlm.nih.gov/pubmed/34692727
http://dx.doi.org/10.3389/fmed.2021.735796
_version_ 1784585977275088896
author Bichon, Amandine
Bourenne, Jérémy
Allardet-Servent, Jérôme
Papazian, Laurent
Hraiech, Sami
Guervilly, Christophe
Pauly, Vanessa
Kaplanski, Gilles
Mokart, Djamel
Gainnier, Marc
Carvelli, Julien
author_facet Bichon, Amandine
Bourenne, Jérémy
Allardet-Servent, Jérôme
Papazian, Laurent
Hraiech, Sami
Guervilly, Christophe
Pauly, Vanessa
Kaplanski, Gilles
Mokart, Djamel
Gainnier, Marc
Carvelli, Julien
author_sort Bichon, Amandine
collection PubMed
description Background: Adult hemophagocytic lymphohistiocytosis (HLH) is highly lethal in the ICU. The diagnostic and therapeutic emergency that HLH represents is compounded by its unknown pathophysiological mechanisms. Here, we report on a large cohort of adult HLH in the ICU (ICU-HLH). We analyzed prognostic factors associated with mortality to define the diagnostic and therapeutic challenges in this specific population. Methods: This retrospective study included adult patients diagnosed with HLH in four ICUs in Marseille, France between 2010 and 2020. Patients who fulfilled the HLH-2004 criteria (≥ 4/8) and/or had an HScore ≥ 169 were diagnosed with HLH. HLH was categorized into four groups according to etiology: sepsis-associated HLH, intracellular infection-associated HLH, malignancy-associated HLH, and idiopathic HLH. Results: Two hundred and sixty patients were included: 121 sepsis-associated HLH (47%), 84 intracellular infection-associated HLH (32%), 28 malignancy-associated HLH (11%), and 27 idiopathic HLH (10%). The ICU mortality rate reached 57% (n = 147/260) without a statistical difference between etiological groups. Independent factors associated with mortality in multivariate analysis included age (OR (5 years) = 1.31 [1.16–1.48], p < 0.0001), SOFA score at ICU admission (OR = 1.37 [1.21–1.56], p < 0.0001), degradation of the SOFA score between ICU arrival and HLH diagnosis (Delta SOFA) (OR = 1.47 [1.28–1.70], p < 0.0001), the presence of bone-marrow hemophagocytosis (OR = 5.27 [1.11–24.97], p = 0.04), highly severe anemia (OR = 1.44 [1.09–1.91], p = 0.01), and hypofibrinogenemia (OR = 1.21 [1.04–1.41], p = 0.02). Conclusions: In this large retrospective cohort study of critically ill patients, ICU-HLH in adults was associated with a 57% mortality rate, regardless of HLH etiology or specific treatment. Factors independently associated with prognosis included age, presence of hemophagocytosis in bone-marrow aspirates, organ failure at admission, and worsening organ failure during the ICU stay. Whether a rapid diagnosis and the efficacy of specific therapy improve outcome is yet to be prospectively investigated.
format Online
Article
Text
id pubmed-8526960
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85269602021-10-21 High Mortality of HLH in ICU Regardless Etiology or Treatment Bichon, Amandine Bourenne, Jérémy Allardet-Servent, Jérôme Papazian, Laurent Hraiech, Sami Guervilly, Christophe Pauly, Vanessa Kaplanski, Gilles Mokart, Djamel Gainnier, Marc Carvelli, Julien Front Med (Lausanne) Medicine Background: Adult hemophagocytic lymphohistiocytosis (HLH) is highly lethal in the ICU. The diagnostic and therapeutic emergency that HLH represents is compounded by its unknown pathophysiological mechanisms. Here, we report on a large cohort of adult HLH in the ICU (ICU-HLH). We analyzed prognostic factors associated with mortality to define the diagnostic and therapeutic challenges in this specific population. Methods: This retrospective study included adult patients diagnosed with HLH in four ICUs in Marseille, France between 2010 and 2020. Patients who fulfilled the HLH-2004 criteria (≥ 4/8) and/or had an HScore ≥ 169 were diagnosed with HLH. HLH was categorized into four groups according to etiology: sepsis-associated HLH, intracellular infection-associated HLH, malignancy-associated HLH, and idiopathic HLH. Results: Two hundred and sixty patients were included: 121 sepsis-associated HLH (47%), 84 intracellular infection-associated HLH (32%), 28 malignancy-associated HLH (11%), and 27 idiopathic HLH (10%). The ICU mortality rate reached 57% (n = 147/260) without a statistical difference between etiological groups. Independent factors associated with mortality in multivariate analysis included age (OR (5 years) = 1.31 [1.16–1.48], p < 0.0001), SOFA score at ICU admission (OR = 1.37 [1.21–1.56], p < 0.0001), degradation of the SOFA score between ICU arrival and HLH diagnosis (Delta SOFA) (OR = 1.47 [1.28–1.70], p < 0.0001), the presence of bone-marrow hemophagocytosis (OR = 5.27 [1.11–24.97], p = 0.04), highly severe anemia (OR = 1.44 [1.09–1.91], p = 0.01), and hypofibrinogenemia (OR = 1.21 [1.04–1.41], p = 0.02). Conclusions: In this large retrospective cohort study of critically ill patients, ICU-HLH in adults was associated with a 57% mortality rate, regardless of HLH etiology or specific treatment. Factors independently associated with prognosis included age, presence of hemophagocytosis in bone-marrow aspirates, organ failure at admission, and worsening organ failure during the ICU stay. Whether a rapid diagnosis and the efficacy of specific therapy improve outcome is yet to be prospectively investigated. Frontiers Media S.A. 2021-10-06 /pmc/articles/PMC8526960/ /pubmed/34692727 http://dx.doi.org/10.3389/fmed.2021.735796 Text en Copyright © 2021 Bichon, Bourenne, Allardet-Servent, Papazian, Hraiech, Guervilly, Pauly, Kaplanski, Mokart, Gainnier and Carvelli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Bichon, Amandine
Bourenne, Jérémy
Allardet-Servent, Jérôme
Papazian, Laurent
Hraiech, Sami
Guervilly, Christophe
Pauly, Vanessa
Kaplanski, Gilles
Mokart, Djamel
Gainnier, Marc
Carvelli, Julien
High Mortality of HLH in ICU Regardless Etiology or Treatment
title High Mortality of HLH in ICU Regardless Etiology or Treatment
title_full High Mortality of HLH in ICU Regardless Etiology or Treatment
title_fullStr High Mortality of HLH in ICU Regardless Etiology or Treatment
title_full_unstemmed High Mortality of HLH in ICU Regardless Etiology or Treatment
title_short High Mortality of HLH in ICU Regardless Etiology or Treatment
title_sort high mortality of hlh in icu regardless etiology or treatment
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526960/
https://www.ncbi.nlm.nih.gov/pubmed/34692727
http://dx.doi.org/10.3389/fmed.2021.735796
work_keys_str_mv AT bichonamandine highmortalityofhlhinicuregardlessetiologyortreatment
AT bourennejeremy highmortalityofhlhinicuregardlessetiologyortreatment
AT allardetserventjerome highmortalityofhlhinicuregardlessetiologyortreatment
AT papazianlaurent highmortalityofhlhinicuregardlessetiologyortreatment
AT hraiechsami highmortalityofhlhinicuregardlessetiologyortreatment
AT guervillychristophe highmortalityofhlhinicuregardlessetiologyortreatment
AT paulyvanessa highmortalityofhlhinicuregardlessetiologyortreatment
AT kaplanskigilles highmortalityofhlhinicuregardlessetiologyortreatment
AT mokartdjamel highmortalityofhlhinicuregardlessetiologyortreatment
AT gainniermarc highmortalityofhlhinicuregardlessetiologyortreatment
AT carvellijulien highmortalityofhlhinicuregardlessetiologyortreatment